Gilead Has Full HIV Policy Agenda For 2019: Part D Challenge; Prophylaxis Increase
Executive Summary
Gilead faces two-pronged policy challenge in its core HIV business: its Part D product line could lose protections, but prophylactic prescriptions could dramatically expand under the Trump Administration's plan to eliminate HIV transmission.